Reports Q1 revenue $0 vs. $7.14M last year. “This quarter reflects continued progress across our pipeline as we advance Phase 1 dose-escalation studies for HWK-007 and HWK-016, with a third IND planned for HWK-206 mid-year,” said Dave Lennon, CEO. “We remain focused on high quality execution as we build toward initial data anticipated in 1H 2027, with the goal of delivering meaningful benefits for patients.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WHWK:
- Whitehawk announces presentation of new preclinical data across ADC portfolio
- Whitehawk Therapeutics management to meet with Oppenheimer
- Whitehawk Therapeutics initiated with an Outperform at Citizens
- Whitehawk Therapeutics presents analysis of MUC16 at SGO
- Whitehawk’s First-in-Human PTK7 ADC Trial Moves Ahead: What Investors Should Know